




PHARMACEUTICAL 2020

Sonoma Pharmaceuticals Inc.
Rank 194 of 358





RealRate

PHARMACEUTICAL 2020

Sonoma Pharmaceuticals Inc. Rank 194 of 358



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 150% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 31% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	12,496
Cost of Goods Sold	10,090
Intangible Assets	0
Liabilities, Current	3,591
Liabilities, Non-Current	12
Other Assets	1,225
Other Compr. Net Income	0
Other Expenses	491
Other Liabilities	356
Other Net Income	-49
Other Revenues	18,970
Property and Equipment	727
Research and Development	1,518
Selling, General and Administrative Expense	18,620

Output Variable	Value in 1000 USD
Assets	14,448
Liabilities	3,959
Expenses	30,719
Revenues	18,970
Stockholders Equity	10,489
Net Income	-11,798
Comprehensive Net Income	-11,798
Economic Capital Ratio	68%